The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

Amsterdam-based UniQure developed AMT-130 to slow progression of Huntington's disease, a fatal, progressive neurodegenerative disease caused by mutations in the huntingtin gene. The gene therapy is ...

After discussions with the FDA, the firm believes it has a regulatory path to bringing Illuccix and Gozellix into the pre-biopsy setting.

NEW YORK – AstraZeneca and Daiichi Sankyo said on Tuesday the European Commission approved its antibody-drug conjugate Enhertu (trastuzumab deruxtecan) in combination with Genentech's HER2 monoclonal ...

Revolution's RAS inhibitor may be approved in an all-comer population, but molecular profiling remains key to treatment ...

The firm is seeking to expand the indication for its siRNA drug, which is already approved for familial chylomicronemia syndrome.

NEW YORK – Abbisko Therapeutics has begun treating cancer patients harboring KRAS alterations with the pan-KRAS Inhibitor ABSK211 in a Phase I trial. The company announced on Monday that the trial ...

BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.

The hospital, which has been making investments into precision medicine, inked a multi-phase deal to integrate PGx into clinical workflows.